MDMA with Mirtazapine

MDMA + Mirtazapine results in:

1. Neurochemical interactions: MDMA (ecstasy) causes the massive release of serotonin, dopamine, and norepinephrine. Mirtazapine blocks 5-HT₂A/₂C and 5-HT₃ receptors and acts as an α₂ antagonist. As a result, mirtazapine can mitigate some acute physical MDMA effects (e.g., less gastrointestinal irritation due to 5-HT₃ blockade). However, mirtazapine does not block serotonin reuptake, meaning MDMA can still release very large amounts of serotonin.

2. Therapeutic effect: Because mirtazapine affects the serotonin system differently than SSRIs, the entactogenic effect of MDMA remains largely intact. SSRIs significantly reduce the effect of MDMA (MDMA requires SERT), but mirtazapine does not. However, mirtazapine's 5-HT₂A blockade can reduce the hallucinogenic side effects of MDMA, possibly reducing vasodilation and nausea (5-HT₃). Some users report less overstimulation or anxiety. Mirtazapine is sedative (H1 block), which can cause some drowsiness after the MDMA dose, but there is no data suggesting that it negatively affects therapy for PTSD or depression with MDMA.

3. Danger or risks: The combined risk of serotonin syndrome is relatively low, because MDMA does not act primarily via SERT blockade. However, due to α₂ blockade, mirtazapine can actually release extra noradrenaline, which can amplify the sympathetic side effects of MDMA (heart rate, blood pressure). In general, both together can lead to a more heightened mood and increased cardiovascular stimulation. However, serotonin syndrome can be a problem at higher doses or in cases of sensitivity, and therefore combined use is always advised against.